Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Medpace (Nasdaq: MEDP) reported first quarter 2026 revenue of $706.6M, up 26.5% year-over-year, GAAP net income of $123.9M ($4.28 diluted), and EBITDA of $149.4M (21.1% margin). Backlog totaled $2,929.2M. Cash and equivalents were $652.7M and operating cash flow was $151.8M.
Full-year 2026 guidance: revenue $2.755B–$2.855B, GAAP net income $487M–$511M, and EBITDA $605M–$635M. President Jesse Geiger will retire effective May 31, 2026.
Medpace (Nasdaq: MEDP) will report first quarter 2026 financial results after market close on April 22, 2026.
The company will host a conference call to discuss results on April 23, 2026 at 9:00 a.m. ET. Webcast, replay, and a supplemental slide presentation will be available in the Investors section at investor.medpace.com. Telephone participants must register in advance.
Summary not available.
Medpace (Nasdaq: MEDP) reported strong fourth-quarter and full-year 2025 results, driven by robust revenue growth and solid bookings.
Q4 revenue was $708.5M (+32.0% YoY) and GAAP net income was $135.1M ($4.67/diluted). Full-year 2025 revenue was $2,530.2M (+20.0% YoY) with GAAP net income of $451.1M ($15.28/diluted). The company repurchased 2,961,924 shares for $912.9M in 2025 and provided 2026 guidance of $2.755B–$2.855B revenue and GAAP net income of $487M–$511M.
Medpace (Nasdaq: MEDP) will report fourth quarter and fiscal year 2025 financial results after market close on Monday, February 9, 2026. The company will host a conference call to discuss results on Tuesday, February 10, 2026 at 9:00 a.m. ET.
Telephone participants must register in advance to receive a confirmation email with dial-in details and a unique PIN. A live webcast, supplemental slide presentation, and a replay (available ~one hour after the call ends) will be available in the Investors section at investor.medpace.com.
Medpace (Nasdaq: MEDP) reported third quarter 2025 revenue of $659.9M, up 23.7% YoY, with net new business awards of $789.6M (+47.9%) and a net book-to-bill of 1.20x. GAAP net income was $111.1M or $3.86 per diluted share; net income margin was 16.8% versus 18.1% a year ago. EBITDA rose 24.9% to $148.4M (22.5% margin). Cash and equivalents were $285.4M and operating cash flow in Q3 was $246.2M. Year-to-date share repurchases totaled 2,961,924 shares for $912.9M, with $821.7M remaining on the buyback. Full‑year 2025 guidance: revenue $2.48–2.53B, GAAP net income $431–439M, EBITDA $545–555M.
Medpace Holdings (NASDAQ:MEDP) has scheduled its third quarter 2025 financial results announcement for October 22, 2025 after market close. The company will host a conference call on Thursday, October 23, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will be available prior to the call.
Medpace Holdings (NASDAQ:MEDP) reported strong Q2 2025 financial results with revenue increasing 14.2% to $603.3 million compared to the prior year. The company achieved a net book-to-bill ratio of 1.03x with net new business awards of $620.5 million, up 12.6% year-over-year.
GAAP net income reached $90.3 million ($3.10 per diluted share), while EBITDA grew 16.2% to $130.5 million with a 21.6% margin. The company's backlog slightly decreased by 1.8% to $2.87 billion. During Q2, Medpace repurchased 1.75 million shares for $518.5 million.
For full-year 2025, Medpace forecasts revenue between $2.42-2.52 billion, representing 14.7-19.5% growth, with GAAP net income expected between $405-428 million.
Medpace Holdings (Nasdaq: MEDP) has scheduled its second quarter 2025 financial results announcement for Monday, July 21, 2025, after market close. The company will host a conference call on Tuesday, July 22, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will be available prior to the call.
Medpace Holdings (MEDP) reported Q1 2025 financial results with revenue reaching $558.6 million, a 9.3% increase from $511.0 million in the prior year. GAAP net income rose to $114.6 million ($3.67 per diluted share), up from $102.6 million ($3.20 per diluted share) year-over-year.
The company's backlog decreased 2.1% to $2.85 billion, with net new business awards of $500.0 million resulting in a book-to-bill ratio of 0.90x. EBITDA grew 2.6% to $118.6 million with a 21.2% margin.
During Q1, Medpace repurchased 1.19 million shares for $389.8 million and received board approval for an additional $1.0 billion share repurchase program. The company projects 2025 revenue between $2.14-2.24 billion, representing 1.5-6.2% growth, with GAAP net income forecast at $378.0-402.0 million.